News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Alper Topal: The Keynote 921 study failed for CRPC
Alper Topal/researchgate.net
Mar 18, 2025, 12:35

Alper Topal: The Keynote 921 study failed for CRPC

Alper Topal, Medical Onoclogist at Gülhane Training and Research Hospital, shared a paper Daniel P. Petrylak and colleagues authored on X:

“The Keynote 921 study failed for CRPC.

mPFS was 8.6 months in the pembro arm compared to 8.3 months in the placebo arm.mOS was 19.6 months in the pembro arm compared to 19 months in the placebo arm. Grade 3≥side effects were more common in the pembro arm.”

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

Authors: Daniel P. Petrylak et al.

Alper Topal

Alper Topal Andrew J. Armstrong Andries M. Bergman cancer Charles Schloss Christian H. Poehlein Daniel P. Petrylak Eric Levesque Ernesto Korbenfeld Gero Kramer Howard Gurney Karim Fizazi Loic Mourey Margitta Retz Maria De Santis Meital Levartovsky Nobuaki Matsubara OncoDaily Oncology Pawel Zalewski Raffaele Ratta Ray Manneh Ray McDermott Russell Pachynski Rustem Gafanov Seok Soo Byun Sergio Bracarda Tilman Todenhofer Winald Gerritsen Xin Tong Li
Special Coverage
Blog
Apr 18, 2025, 20:22
Applications are open for the ESMO Research Fellowship
Blog
Apr 18, 2025, 20:12
Caitríona Duggan: Delighted for the opportunity to share our work at MASCC
Blog
Apr 18, 2025, 20:03
Fumiko Ladd Chino: Honored to be invited to speak about financial toxicity
Blog
Apr 18, 2025, 20:02
Estelamari Rodriguez: ACS NLCRT Biomarker Workshop version of brainstorming with the stars
Blog
Apr 18, 2025, 19:54
Sami Mansfield: Fiber, the microbiome, and cancer care
Blog
Apr 18, 2025, 19:49
Eric K. Singhi Discusses Lung Cancer at ASCO 2025
Science
Apr 18, 2025, 19:44
Nirmala Bhoo Pathy: The need for race and ethnicity data in cancer control
Science
Apr 18, 2025, 19:28
Andreas Charalambous: Achieving digital transformation in cancer care across Europe
Blog
Apr 18, 2025, 19:26
SIOG - Older adults deserve better: Let’s close the gap in Cancer Care
Science
Apr 18, 2025, 19:10
Rafael Grochot: The safety and activity of FGFR inhibitors in early-phase clinical trials
Blog
Apr 18, 2025, 18:58
Mission Adaptation and Mission Cancer: Resilient Health Systems for Cancer - ECHoS
Blog
Apr 18, 2025, 18:55
Robert F. Kennedy Jr. visited U.S. FDA with Commissioner Martin Makary on Medical Innovation